Helmholtz Gemeinschaft


Investigational drugs in development to prevent neuromyelitis optica relapses

Item Type:Review
Title:Investigational drugs in development to prevent neuromyelitis optica relapses
Creators Name:Paul, F., Murphy, O., Pardo, S. and Levy, M.
Abstract:INTRODUCTION: In the short time since 2014, three pivotal, worldwide studies in neuromyelitis optica spectrum disorders have been launched: eculizumab, SA237 and inebelizumab, each based on a unique mechanism. AREAS COVERED: In this review, we provide a discussion on the trial data available for each drug, a brief description of the trial design, and our expert opinion on the potential benefits and risks. EXPERT OPINION: Eculizumab, a C5 complement inhibitor, may prove useful in the treatment of intractable cases of NMOSD, but physicians must be aware of the known risk of meningococcal infection. SA237, an interleukin-6 receptor blocker, may be effective at reducing relapse risk, and also has the potential to reduce neuropathic pain in NMOSD. Inebelizumab, a B cell depleting agent, has never been tested in NMOSD, but based on extensive evidence of efficacy with B cell depletion using rituximab, inebelizumab is expected to work at least as well.
Keywords:Neuromyelitis Optica, Biomarkers, Prognosis, Risk Assessment
Source:Expert Opinion on Investigational Drugs
Publisher:Taylor & Francis
Page Range:265-271
Date:March 2018
Official Publication:https://doi.org/10.1080/13543784.2018.1443077
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library